Processes for quantifying an amount of functional groups immobilized on a solid support are described herein. The processes allow for determining whether sufficient functional groups are provided on a solid support for the attachment of a first binding pair member for the detection of a target analyte.

Processes for quantifying an amount of functional groups immobilized on a solid support are described herein. The processes allow for determining whether sufficient functional groups are provided on a solid support for the attachment of a first binding pair member for the detection of a target analyte.

An indicator of a first type and an indicator of a second type are attached to a unit of a chemical component in a sample to form a first multi-indicator complex. The first multi-indicator complex includes the unit of the chemical component, the indicator of the first type, and the indicator of the second type. The indicator of the first type and the indicator of the second type have different discernible characteristics. An image of the sample, including the first multi-indicator complex corresponding to the unit of the chemical component, is captured by an image sensor. Based on a first image of the sample, a count is generated of multi-indicator complexes that include an indicator of the first type and an indicator of the second type, including the first multi-indicator complex. Based on the count, a presence or a level of the chemical component in the sample is identified.

An indicator of a first type and an indicator of a second type are attached to a unit of a chemical component in a sample to form a first multi-indicator complex. The first multi-indicator complex includes the unit of the chemical component, the indicator of the first type, and the indicator of the second type. The indicator of the first type and the indicator of the second type have different discernible characteristics. An image of the sample, including the first multi-indicator complex corresponding to the unit of the chemical component, is captured by an image sensor. Based on a first image of the sample, a count is generated of multi-indicator complexes that include an indicator of the first type and an indicator of the second type, including the first multi-indicator complex. Based on the count, a presence or a level of the chemical component in the sample is identified.

The present disclosure in some aspects provides methods for the controlled merging of emulsion droplets, which can be used to assemble useful compositions such as droplets (e.g., stabilized micelles) containing a precise combination of analytes and/or analytical reagents. In some embodiments, disclosed herein is a method, e.g., for detecting the presence/absence, a level or amount, and/or an activity of an analyte in a sample, comprising merging two or more emulsion droplets such that an interaction between an analyte and an analyte-interacting reagent occurs in the merged droplet. The two or more emulsion droplets may be merged using a method for the controlled merging of emulsion droplets disclosed herein.

Herein is reported a method for the determination of the presence of anti-drug antibodies in a sample comprising the steps of incubating the sample with MgCl.sub.2 at a final concentration in the range of 1 N to 12 N; adding a tracer antibody and incubating the sample thereafter; incubating the isolated tracer antibody-anti-drug antibody-complexes with a detection antibody conjugated to a detectable label and determining the presence of anti-drug antibodies if a signal above a threshold level is obtained.

Herein is reported a method for the determination of the presence of anti-drug antibodies in a sample comprising the steps of incubating the sample with MgCl.sub.2 at a final concentration in the range of 1 N to 12 N; adding a tracer antibody and incubating the sample thereafter; incubating the isolated tracer antibody-anti-drug antibody-complexes with a detection antibody conjugated to a detectable label and determining the presence of anti-drug antibodies if a signal above a threshold level is obtained.

The present application discloses methods and apparatus for detecting a complex including an analyte that include contacting a sample in a solution with a population of functionalized beads of a first type, which are magnetic functionalized beads and are functionalized to include a first moiety that associates with an analyte under suitable conditions, contacting the sample solution with a population of functionalized beads of a second type, which are functionalized to include a second moiety that associates with the analyte under suitable conditions, contact resulting in formation of a complex including one of the first type of functionalized bead, the analyte, and one of the second type of functionalized bead, and detecting the complex including the analyte by detecting magnetic fields produced by the magnetic functionalized bead and by detecting the functionalized bead of the second type associated with the analyte in the complex.

The present application discloses methods and apparatus for detecting a complex including an analyte that include contacting a sample in a solution with a population of functionalized beads of a first type, which are magnetic functionalized beads and are functionalized to include a first moiety that associates with an analyte under suitable conditions, contacting the sample solution with a population of functionalized beads of a second type, which are functionalized to include a second moiety that associates with the analyte under suitable conditions, contact resulting in formation of a complex including one of the first type of functionalized bead, the analyte, and one of the second type of functionalized bead, and detecting the complex including the analyte by detecting magnetic fields produced by the magnetic functionalized bead and by detecting the functionalized bead of the second type associated with the analyte in the complex.

The present disclosure relates to a method for simultaneous detection of antigens and antigen specific antibodies. LIBRA-seq (Linking B Cell Receptor to Antigen specificity through sequencing) is developed to simultaneously recover both antigen specificity and paired heavy and light chain BCR sequence. LIBRA-seq is a next-generation sequencing-based readout for BCR-antigen binding interactions that utilizes oligonucleotides (oligos) conjugated to recombinant antigens.